Immune Pharmaceuticals signs licensing agreement for AmiKet

Immune Pharmaceuticals, Inc., said Monday it entered into a definitive license and research agreement with Yissum to license some Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet. AmiKet, a topical drug for the treatment of neuropathic pain, has undergone trials involving more than 1,700 patients demonstrating comparable effectiveness to the high dose of the oral standard of care, gabapentin in a double-blind, placebo-controlled Phase II c Read More »